Patents by Inventor Joseph R. Naemura

Joseph R. Naemura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATMENT USING CTLA4 MUTANT MOLECULES
    Publication number: 20120052065
    Abstract: The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.
    Type: Application
    Filed: October 20, 2011
    Publication date: March 1, 2012
    Inventors: Robert J. Peach, Joseph R. Naemura, Peter S. Linsley, Jurgen Bajorath
  • METHODS OF TREATMENT USING CTLA4 MUTANT MOLECULES
    Publication number: 20100183612
    Abstract: The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.
    Type: Application
    Filed: January 27, 2010
    Publication date: July 22, 2010
    Inventors: Robert J. Peach, Joseph R. Naemura, Peter S. Linsley, Jurgen Bajorath
  • Methods of treatment using CTLA4 mutant molecules
    Publication number: 20090041769
    Abstract: The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.
    Type: Application
    Filed: March 20, 2007
    Publication date: February 12, 2009
    Inventors: Robert J. Peach, Joseph R. Naemura, Peter S. Linsley, Jurgen Bajorath
  • Methods of treatment using CTLA4 mutant molecules
    Patent number: 7439230
    Abstract: The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.
    Type: Grant
    Filed: November 3, 2004
    Date of Patent: October 21, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Robert J. Peach, Joseph R. Naemura, Peter S. Linsley, Jurgen Bajorath
  • Soluble CTLA4 mutant molecules and uses thereof
    Publication number: 20030219863
    Abstract: The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wildtype CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 and M97-G107 are mutated. The mutant molecules of the invention also include a second amino acid sequence which increases the solubility of the mutant molecule.
    Type: Application
    Filed: January 2, 2003
    Publication date: November 27, 2003
    Applicant: Bristol-Myers Squibb Company
    Inventors: Robert J. Peach, Joseph R. Naemura, Peter S. Linsley, Jurgen Bajorath
  • Soluble CTLA4 mutant molecules and uses thereof
    Publication number: 20020182211
    Abstract: The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.
    Type: Application
    Filed: May 23, 2001
    Publication date: December 5, 2002
    Inventors: Robert J. Peach, Joseph R. Naemura, Peter S. Linsley, Jurgen Bajorath